Yağcı, A. M. 2022. Residual Disease Kinetics Among Patients with High-Risk Factors Treated with First-Line Fixed-Duration Ibrutinib Plus Venetoclax (Ibr+Ven) Versus Chlorambucil Plus Obinutuzumab (Clb+O): The Glow Study. ASH , (Louisiana, United States Of America), 228-230.

Yağcı, A. M., (2022). Residual Disease Kinetics Among Patients with High-Risk Factors Treated with First-Line Fixed-Duration Ibrutinib Plus Venetoclax (Ibr+Ven) Versus Chlorambucil Plus Obinutuzumab (Clb+O): The Glow Study . ASH (pp.228-230). Louisiana, United States Of America

Yağcı, ABDULLAH. "Residual Disease Kinetics Among Patients with High-Risk Factors Treated with First-Line Fixed-Duration Ibrutinib Plus Venetoclax (Ibr+Ven) Versus Chlorambucil Plus Obinutuzumab (Clb+O): The Glow Study," ASH, Louisiana, United States Of America, 2022

Yağcı, ABDULLAH M. . "Residual Disease Kinetics Among Patients with High-Risk Factors Treated with First-Line Fixed-Duration Ibrutinib Plus Venetoclax (Ibr+Ven) Versus Chlorambucil Plus Obinutuzumab (Clb+O): The Glow Study." ASH , Louisiana, United States Of America, pp.228-230, 2022

Yağcı, A. M. (2022) . "Residual Disease Kinetics Among Patients with High-Risk Factors Treated with First-Line Fixed-Duration Ibrutinib Plus Venetoclax (Ibr+Ven) Versus Chlorambucil Plus Obinutuzumab (Clb+O): The Glow Study." ASH , Louisiana, United States Of America, pp.228-230.

@conferencepaper{conferencepaper, author={ABDULLAH MÜNCİ YAĞCI}, title={Residual Disease Kinetics Among Patients with High-Risk Factors Treated with First-Line Fixed-Duration Ibrutinib Plus Venetoclax (Ibr+Ven) Versus Chlorambucil Plus Obinutuzumab (Clb+O): The Glow Study}, congress name={ASH}, city={Louisiana}, country={United States Of America}, year={2022}, pages={228-230} }